Effect of Ovarian Cancer Ascites on Cell Migration and Gene Expression in an Epithelial Ovarian Cancer In Vitro Model  by Meunier, Liliane et al.
Effect of Ovarian Cancer Ascites
on Cell Migration and Gene
Expression in an Epithelial
Ovarian Cancer In Vitro Model1
Liliane Meunier*,2, Marie-Line Puiffe*,2,
Cécile Le Page*, Abdelali Filali-Mouhim*,
Mario Chevrette†,‡, Patricia N. Tonin†,§,¶,
Diane M. Provencher*,#
and Anne-Marie Mes-Masson*,**
*Centre de recherche du Centre hospitalier de l’Université de
Montréal/Institut du cancer de Montréal, Montreal, Quebec,
Canada; †The Research Institute of McGill University Health
Centre, Montreal, Quebec, Canada; ‡Department of Surgery,
Urology Division, McGill University, Montreal, Quebec,
Canada; §Department of Medicine, McGill University,
Montreal, Quebec, Canada; ¶Department of Human Genetics,
McGill University, Montreal, Quebec, Canada; #Division of
Gynecologic Oncology/Université de Montréal, Montreal,
Quebec, Canada; **Département de médecine, Université de
Montréal, Montreal, Quebec, Canada
Abstract
A third of patients with epithelial ovarian cancer (EOC) present ascites. The cellular fraction of ascites often consists
of EOC cells, lymphocytes, and mesothelial cells, whereas the acellular fraction contains cytokines and angiogenic
factors. Clinically, the presence of ascites correlates with intraperitoneal and retroperitoneal tumor spread. We have
used OV-90, a tumorigenic EOC cell line derived from the malignant ascites of a chemonaive ovarian cancer patient,
as a model to assess the effect of ascites on migration potential using an in vitro wound-healing assay. A recent
report of an invasion assay described the effect of ascites on the invasion potential of the OV-90 cell line. Ascites
sampled from 31 ovarian cancer patients were tested and compared with either 5% fetal bovine serum or no serum
for their nonstimulatory or stimulatory effect on the migration potential of the OV-90 cell line. A supervised analysis of
data generated by the Affymetrix HG-U133A GeneChip identified differentially expressed genes from OV-90 cells
exposed to ascites that had either a nonstimulatory or a stimulatory effect on migration. Ten genes (IRS2, CTSD,
NRAS, MLXIP, HMGCR, LAMP1, ETS2, NID1, SMARCD1, and CD44) were upregulated in OV-90 cells exposed to
ascites, allowing a nonstimulatory effect on cell migration. These findings were validated by quantitative polymerase
chain reaction. In addition, the gene expression of IRS2 andMLXIP each correlated with prognosis when their expres-
sion was assessed in an independent set of primary cultures established from ovarian ascites. This study revealed
novel candidates that may play a role in ovarian cancer cell migration.
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Introduction
Ovarian cancer is the fifth cause of cancer-related deaths in woman
and the most lethal of all gynecological cancers. Largely asymptomatic,
more than 70% of patients with ovarian cancer have already reached an
advanced stage of disease at initial diagnosis [1,2], and the overall 5-year
survival rate for these patients is less than 30% [3]. Intraperitoneal dis-
semination is common, and malignant cells can implant anywhere in
the peritoneal cavity but are more likely to implant in sites of stasis
along the peritoneal fluid circulation [4]. Ascites, a voluminous exuda-
tive fluid with a cellular fraction consisting of ovarian cancer cells, lym-
phocytes, and mesothelial cells, is present in more than one-third of
ovarian cancer patients. The acellular fraction is known to harbor cyto-
kines and angiogenic factors [5–9]. Clinically, the presence of ascites
correlates with intraperitoneal and retroperitoneal tumor spread, sug-
gesting that it may facilitate metastasis [10].
Previously, we used an in vitro invasion assay to monitor the effect
of ascites on the potential of chemonaive epithelial ovarian cancer
(EOC) cell lines to degrade and migrate across a Matrigel-based bar-
rier [11]. We used the OV-90 cell line to perform our assays. This
cell line is derived from an ovarian malignant ascites, is able to form
tumors in a xenograft model, and has been extensively characterized
at both the cellular and the molecular levels [11–13]. Ascites from
more than 50 patients were tested and compared with either 5% fetal
bovine serum (FBS) or no serum in an invasion assay. The ascites
were classified into one of two categories for their effect on invasion
on the basis of comparison to FBS-treated cells: stimulatory (≥5%
FBS activity) or nonstimulatory (<20% of FBS activity). We focused
on gene expression profiles generated from the OV-90 cell line [12]
treated with ascites possessing either stimulatory or nonstimulatory
invasive potential. A supervised analysis of gene expression micro-
array data sets identified differentially expressed genes, which were
validated by quantitative polymerase chain reaction (Q-PCR) assays
on the basis of OV-90 cells exposed to a large number of ascites from
different patients. In a previous study [11], the proliferation rates and
the capacity to form three-dimensional spheroids in hanging drop
cultures of the OV-90 cell line treated with different ascites were also
described. The results from this previous study strongly supported
the notion that ascites affect the cellular and molecular behaviors
of ovarian cancer cells.
In the present study, we have further assessed the effect of the same
ascites samples on the migration potential of OV-90 cells using an
in vitro wound-healing assay and extended our analysis to include a
larger number of ascites samples derived from ovarian cancer patients.
We also assessed differential gene expression using OV-90 cells treated
with no serum, with 5% of ascites, or with 5% FBS that correlated
with the cellular migration potential of this cell line. Some candidate
genes identified in our analysis were further validated using Q-PCR,
and their association with survival was tested in an independent set of
primary cultures derived from ovarian cancer patients with ascites.
Materials and Methods
Cell Culture Conditions, Material, and Patients
OV-90 cells were maintained in ovarian surface epithelium (OSE)
complete medium (cat. no. 316-030-CL; Wisent, Quebec, Canada)
supplemented with 10% FBS, 2.5 μg/ml of amphotericin B (Wisent),
and 50 μg/ml of gentamicin (Invitrogen, Ontario, Canada) at 37°C
[14]. Ascites were collected at the time of clinical intervention from
ovarian cancer patients at the Centre hospitalier de l’Université de
Montréal (Montreal, Quebec, Canada). Informed consent for this study
was obtained from all of the patients. After centrifuging at 1250g for
5 minutes, the acellular fractions of ascites were stored at −20°C and
testedwithin 6months of collection.Histopathological diagnosis, grade,
and stage of ovarian tumor samples were assigned according to the
criteria of the International Federation of Gynecology and Obstetrics.
Of the 31 ascites samples, one third were from patients diagnosed with
papillary serous adenocarcinoma andmost presented as stage IIIC grade 3
tumordiseases (Table 1). A small proportion (4/31) of patients had already
received chemotherapy before ascites collection. The cohort of patients
with ovarian cancer and the accompanying ascites used for this research
and included in the survival analysis have been described previously [11].
In Vitro Migration Assays
Cellular migration was assayed by determining the ability of cells
to migrate in a culture plate using a wound-healing assay. To evaluate
migration assays, OV-90 cells were plated in 12-well dishes and were
grown at 37°C until confluent. Cell monolayers were scraped using
a sterile 200-μl yellow plastic tip to produce small wounds of simi-
lar size. Wounded monolayers were then washed with phosphate-
buffered saline to remove cell debris, and OSE medium was added
with no serum or with either 5% FBS or 5% ascites. For inactivation
assays, ascites were heated for 10 minutes at 100°C to denature the
proteins. Cells were incubated at 37°C under 5% CO2 for different
lengths of time to evaluate their migration (0, 6, 24, 30, 48, and
54 hours after scratch formation). At the different time points, cells
were methanol-fixed and treated with Giemsa stain (Sigma-Aldrich,
Inc, St Louis, MO). Digital images were obtained at each time point
of the experiment. Images were analyzed, and wound closures were
quantified using Image Pro Plus software (Version 5.1; MediaCyber-
netics, Bethesda, MD) and Microsoft Excel. All experiments were
performed twice using triplicate samples and were normalized to
FBS-treated cultures.
RNA Preparation
Total RNA was extracted using TRIzol reagent (Gibco/BRL, Life
Technologies, Inc, Grand Island, NY) according to the manufacturer’s
protocol. RNA was extracted from OV-90 cells grown to 80% conflu-
ence in 100-mm Petri dishes. The quality of RNA was assessed using a
2100 Bioanalyzer with the RNA 6000 Nano LabChip kit (Agilent
Technologies, Mississauga, Ontario, Canada) according to the manu-
facturer’s protocol.
Microarray hybridization experiments were performed at McGill
University and the Genome Quebec Innovation Center (Montreal,
Quebec, Canada) using the HG-U133A GeneChip arrays. This chip
allows the analysis of approximately 18,400 transcripts and variants,
including 14,500 well-characterized human genes, composed of more
than 22,000 probe sets. Protocols are available at the Affymetrix Web
site (www.affymetrix.com; Affymetrix, Santa Clara, CA). Methods for
labeling and hybridization of RNA were previously described [11].
Gene Expression Statistical Analysis
Gene expression profiles were analyzed using R (version 2.4.0;
www.r-project.org), a statistical programming language, Bioconductor
[15], and an open-source software library for the analyses of genomic
data, which is based on R. Background subtraction, normalization
(quantile normalization), and expression value calculations were per-
formed using the justGCrma function available as part of the Biocon-
ductor’s gcrma package. Bioconductor’s gene filter package was used to
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filter genes with insufficient variation in expression across all samples
tested. Expression values retained after this filtering process had inten-
sities greater than 100 units in at least two samples and a log base 2 scale
of at least 0.2 for the interquartile range across all tested samples. Dif-
ferentially expressed genes were identified using Bioconductor’s limma
package that implements moderate t tests by fitting a linear model for
each group of samples and using empirical Bayes method to moderate
SEs of the estimated log-fold changes between the predefined groups.
Kaplan-Meier survival plots, univariate Cox proportional hazard
regressions, as well as log-rank tests were performed to determine
the significance of using gene expression levels to predict survival
of EOC patients as described earlier [11]. The expression threshold
cutoff was determined by survival tree using the recursive partition-
ing and regression tree (RPART) method [16]. The survival analysis
and tree building were performed using R’s survival and RPART
packages, respectively. The Pearson correlation coefficient test (two-
tailed) was used to calculate the correlation between gene expression
and migration rate and was performed with SPSS software 11.0
(SPSS, Inc, Chicago, IL).
Quantitative Reverse Transcription–PCR Validation
The complementary DNA synthesis was prepared using the
QuantiTech Reverse Transcription for two-step reverse transcription–
PCR (Qiagen, Inc, Mississauga, Ontario, Canada) according to the
manufacturer’s instruction. First-strand synthesis for reverse transcription–
PCR was performed with 1 μg of RNA and a mix of Oligo dT and
random hexamers. Samples were diluted 1:10 in water before Q-PCR.
Q-PCR was performed using Rotor-gene 3000 (Corbett Research,
Montreal Biotech, Inc, Montreal, Quebec, Canada). The Quantitect
SYBR Green PCR (Qiagen, Inc) reaction mixture was used to label
5 μl of sample complementary DNA and 10 pg of the different primers
in a final volume of 25 μl. Reactions were performed at least twice
according to the manufacturer’s instructions. Serial dilutions were per-
formed to generate a standard curve for each gene tested to define the
efficiency of the Q-PCR, and a melt curve was constructed to confirm
reaction specificity. The analytical method of Pfaffl [17] was used to
measure the relative quantity of gene expression. The first sample (with
5% FBS) served as the reference sample in each experiment. Gene ex-
pression was evaluated in the OV-90 cell line with no serum or with
either 5% FBS or 5% ascites, under the same conditions used to eval-
uate the migration potential of the OV-90 cell line. β-Actin was used as
reference gene on the basis of its stable expression in all samples by
microarray analysis. For every marker, a Pearson correlation was calcu-
lated between the scored migration result (1 < 100% and 2 ≥ 100% of
migration) and the scored gene expression (1 < median and 2 ≥median).
All experiments were performed in duplicate.
Results
Effect of Ascites on OV-90 Migration Potential
Ascites from 31 EOC patients were studied to determine their
effect on OV-90 cell migration in an in vitro scratch assay (Table 1
and Figure 1). Cells were grown in a monolayer until confluence in a
Table 1. Compiled Clinical Characteristics of Patients from Which Ascites Were Obtained.
Ascites Age (years) Histopathological Diagnosis Grade Stage Neoplastic Cells in Ascites Previous Chemotherapy Ascites Collected
A3331 73 AC N/S IIIC N/S N/S N/S
A3312 62 MCT 0 N/S Yes N/S Primary surgery
A3294 38 PSA 3 IIIC Yes No Primary surgery
A3258 58 MMT 3 IIIC Yes No Primary surgery
A3203 77 PSA 3 IV Yes No Primary surgery
A3133 52 PSA 3 IIIC Yes No Secondary cytoreduction
A2965 70 MCA 3 IIIC Yes No Primary surgery
A2912 53 PSA 3 IIIC Yes No Primary surgery
A2910 65 OT N/S N/S No N/S Primary surgery
A2891 50 MCA 3 IC N/S No Primary surgery
A2839 54 SA 3 IV N/S No Primary surgery
A2834 62 PSA 3 IIIC Yes No Primary surgery
A2775 48 PSA 2 IIIC Yes No Primary surgery
A2774 41 EA 3 IB N/S No Primary surgery
A2685 61 PSC N/S N/S No N/S Primary surgery
A2652 49 MCT 0 N/S N/S N/S Primary surgery
A2647 68 SA 3 III Yes N/S Primary surgery
A2635 50 MC N/S N/S N/S N/S Primary surgery
A2473 71 MpA 2 IIIC Yes No Primary surgery
A2433 50 MCT 0 IA No N/S Primary surgery
A2427 70 AF N/S IB N/S N/S Primary surgery
A2295 59 SA 3 IIIC Yes No Primary surgery
A2295(2)* 59 SA 3 IIIC Yes Yes Secondary cytoreduction
A2090† 76 UA N/S IIIC N/S Yes N/S
A2085† 65 PSA 3 IIIC N/S Yes Secondary cytoreduction
A1946† 75 PSA 3 IIIC Yes No Primary surgery
A1835† 69 PSA 3 IIIC Yes No Primary surgery
A1592† 35 MCA 3 IIIC N/S No Primary surgery
A1337† 45 PSA 3 IIIC Yes No Primary surgery
A1322† 71 PSA 3 IIIC Yes No Primary surgery
A1317† 60 PSA 3 IV No Yes Primary surgery
AC indicates adenocarcinoma; AF, adenofibroma; EA, endometrioid adenocarcinoma; MC, mucinous cystadenoma; MCA, mixed cell adenocarcinoma; MCT, mucinous cystic tumor in extreme cases of
the malignity; MMT, mixed mullerian tumor; MpA, mucipare adenocarcinoma; MsA, mucinous adenocarcinoma; N/S, not specified; OT, ovarian torsion; PSA, papillary serous adenocarcinoma; PSC,
papillary serous cystadenoma; SA, serous adenocarcinoma; SC, serous cystadenoma; UA, undifferentiated adenocarcinoma.
*Denotes second ascites collected from patient with the same number.
†Results previously reported in Puiffe et al. [11].
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12-well plate. After scratching the monolayer with a pipet tip, cells
were maintained in medium with or without 5% FBS. To test the
effect of ascites, FBS was replaced by 5% ascites (acellular fraction)
from EOC patients and sampled after 0, 6, 24, 30, 48, and 54 hours
of incubation. OV-90 cells are able to seal the wound in 48 hours,
similar to the average seen in comparable EOC cell lines [18]. The
influence of each ascites sample on cell migration was scored in
comparison to medium supplemented with 5% FBS (Figure 1). In
OV-90 cells, a difference in cell migration was observed between cells
in contact with medium alone and cells in medium supplemented
with 5% FBS. When cells were incubated with the medium without
FBS (Figure 1B), cell migration was reduced by 40% in comparison
to 5% FBS. In contrast, a large number of ascites samples (n = 23)
stimulated OV-90 cell migration at levels similar to 5% FBS (Fig-
ure 1B). A smaller number of ascites samples (n = 8) did not stimulate
cell migration when compared with migration in the presence of FBS
(Figure 1B).
To determine whether the migration effect of ascites is protein
component-dependant, two stimulatory and two nonstimulatory as-
cites were selected and heated for 10 minutes at 100°C before adding
to the OV-90 cell cultures (Figure 2). The results suggest that protein
inactivation abolished the stimulatory effect (FBS, A2647 and A2839).
For the two nonstimulatory ascites, samples A2295(2) and A2090,
we also observed a decreased effect on cell migration from ascites that
had been heat-treated. The pH of FBS and the four ascites was not
altered by heating (data not shown).
Effect of Ascites on Gene Expression in OV-90 Cells
To identify potential molecular players in migration regulated by
ascites, gene profiling analysis was performed. Total RNA was ex-
tracted from OV-90 cells after a 24-hour exposure to no serum,
5% FBS, or 5% of one of eight ascites sampled from ovarian cancer
patients as previously described (Table 1) [11]. The RNA samples
were each hybridized on Affymetrix HG-U133A GeneChip arrays,
and gene expression profiles were analyzed using 6489 probe sets
(see Materials and Methods). A supervised analysis was performed
using expression data sets representing the following groups. The
GSTIMUL group contained the ascites (A1946, A1835, A2085,
A1337, and A1592) that stimulated cell migration and included the
5% FBS control. The GnSTIMUL group contained ascites (A1322,
A1317, and A2090) that demonstrates less cell migration and included
the no-FBS sample. This supervised analysis identified 129 genes that
Figure 1. Effect of ascites on OV-90 cell migration. Migration was assessed by determining the ability of cells to migrate in a culture
plate using a wound-healing assay in the presence of ascites compared with 5% FBS (% migration) after 54 hours of incubation. The
symbol “0” indicates medium without ascites or FBS. (A) Effect of FBS and ascites on OV-90 cell migration. (B) Migration profile of OV-90
with OSE medium in the presence or absence of 5% FBS or with 5% of several ascites. (C) Effect of 31 ascites on OV-90 cell migration
potential. (D) Migration profile of OV-90 with OSE medium in the presence or absence of 5% FBS or with 5% of ascites. *Statistical sig-
nificance, P < .05.
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were differentially expressed (P < .05, t test) between the GSTIMUL
and GnSTIMUL groups (Table 2).
Differential Expression Validation of Selected Candidates
by Q-PCR
Forty gene candidates involved in the migration potential of OV-90
cells were selected for further validation by Q-PCR on the basis of their
P values obtained in the previous microarray analysis and also on their
gene functions.The candidates tested byQ-PCRaredescribed inTable 2.
Of the 40 selected genes, 21 were downregulated in the GnSTIMUL
group (HIST1H2AC, F1P1L1, RBM10, H2BS, BTG3, CNTNAP2,
IGF1R, DKC1, HIST1H2BD, CDCA4, MDC1, SMARCD3, TSTA3,
SMARCD2, PDPK1, ADAMTS1, ASH2L, SMARCA4/BRG1,
CMKOR1, ANAPC5, and GPR125) and 19 were upregulated in the
GnSTIMUL group (HSPA1B, CALM3, IRS2, CBFB, CEBPA, LIPG,
CRLF1, MDK, CTSD, NRAS, MLXIP, HMGCR, CALM1, LAMP1,
MKRN1, ETS2, NID1, SMARCD1, and CD44 ). Q-PCR was per-
formed on RNA derived from OV-90 cells exposed individually to the
entire panel of 31 ascites (Table 1). The relative expression ratio of each
candidate, based on the Pfaffl method, was quantified, and for each ex-
periment, the median ratio was calculated, and the result was categorized
as above or below the median expression. Pearson correlations were
calculated for the migratory effect (stimulatory or nonstimulatory) of
each ascites with a gene expression score, as shown in Table 3. Of the
40 candidates, 10 (IRS2, CTSD, NRAS, MLXIP, HMGCR, LAMP1,
ETS2,NID1, SMARCD1, and CD44 ) tested by Q-PCR correlated sig-
nificantly with the ascites migration effect. Three candidates (MDC1,
SMARCA4, and GPR125) correlated significantly, but their down-
regulated expression pattern by Q-PCR was in the opposite direction
expected from the microarray expression analysis.
Survival
In a previous study [11], we showed that the genes exhibiting a
significant correlation with ascites invasion effect could be good prog-
nosis predictors. The prognostic potential of the candidate genes that
Q-PCR expression correlated significantly with the ascites migration
effect was evaluated using microarray expression in 28 primary cultures
derived from the cellular fraction of ascites of ovarian cancer patients.
A survival tree was used to determine the expression cutoff that could
lead to the identification of prognostic groups among patients. In the
case of IRS2 andMLXIP, Kaplan-Meier curves coupled with a log-rank
test identified a patient group with an overall good survival rate asso-
ciated with a high expression (Figure 3). A trend toward significance
was observed for the HMGCR candidate, although its association be-
tween gene expression and patient survival was not significant (P =
.061; Figure 3).
Discussion
EOC is the secondmost common gynecological cancer and accounts for
more than half of the deaths associated with gynecological pelvic malig-
nancies [19,20]. This gynecological malignancy is associated with vague
symptoms, which results in a diagnosis at a late stage [2]. The need for
reliable biomarkers in ovarian cancer detection is increasing because
EOC mortality has not significantly decreased during the past years
because of a poor understanding of the biology [4]. Although ascites
are commonly found in patients with EOC, its association with a poor
prognostic factor is not universally accepted, and mechanisms that lead
to ascites formation are not well characterized in EOC [10,21,22]. The
presence of ascites correlates with intraperitoneal and retroperitoneal
tumor spread, which supports a role inmetastasis [2,10]. It is also known
that ascites contain factors that increase vascular permeability [5]. In this
study, we assessed the effects of ascites on OV-90 cell migration and cor-
related this effect with the alteration of gene expression that occurred in
the same cell line as a consequence of exposure to several heterologous
ascites obtained in different clinical settings (Table 1) [12].
In control tests, the presence of FBS in culture medium stimulated
the cellular migration of the OV-90 cell line. An analysis of the migra-
tion behavior of OV-90 with 31 different ascites showed that more than
two-thirds of the ascites samples stimulated cell migration in a fashion
similar to the serum control. In contrast, one-third of the ascites did not
stimulate migration in a fashion similar to the non-FBS control. Of
the ascites samples collected from the same patient (A2295 and
A2295(2), respectively) but at different times during the course of
her treatment, it is interesting that the prechemotherapy ascites stimu-
lated cell migration, whereas the postchemotherapy ascites inhibited
cell migration. This observation raises the intriguing possibility that
chemotherapy treatment is associated with a diminution of tumor cell
migratory potential but requires validation with a larger sample set.
In a previous study, we determined how ascites affected the inva-
sive capacity of OV-90 cells [11]. Because several of the ascites tested
in that study were also tested in the present study, we looked for cor-
relations between the migration and invasion results. Although some
ascites were able to increase both the migratory and the invasive prop-
erties of OV-90 cells, no correlation was observed between ascites stim-
ulating migration and invasion (data not shown), suggesting that these
two events are activated by different stimuli. Both the stimulatory and
nonstimulatory effects of selected ascites and FBS were lost when the
samples were heated. With this treatment, the results were similar to
those observed with the medium lacking FBS, suggesting that the ef-
fects of FBS and both stimulatory and nonstimulatory ascites were
due to the presence of a protein or a protein component rather than
other soluble factors.
Gene expression was assessed to link molecular events with the
migration effect of ascites. For this purpose, RNA from OV-90 cells
exposed to five stimulatory ascites or 5% FBS (GSTIMUL) were
compared with RNA from cells in the absence of serum or treated
Figure 2. Effect of heat-treated ascites in OV-90 cell migration as-
says in vitro. Both stimulatory (A2647 andA2839) and nonstimulatory
(A2295(2) and A2090) ascites were heated at 100°C for 10 minutes
to inactivate the proteins before adding to OV-90 cell culture media.
The effect on cell migration was subsequently evaluated. *P < .05,
**P < .01.
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Table 2. List of Differentially Expressed Genes among the GSTIMUL and GnSTIMUL Groups That Were Tested in Q-PCR.
P Gene Expression
Level in the
GnSTIMUL*
Probe
Set
HG-U133A
UniGene Description Symbol Molecular Function (Gene Oncology) Cytoband
.004 Down 215071_s_at Hs,484950 Histone 1, H2ac HIST1H2AC DNA binding 6p21,3
.004 Down 221007_s_at Hs,518760 FIP1-like 1 (Saccharomyces cerevisiae) FIP1L1 RNA binding 4q12
.018 Down 208984_x_at Hs,401509 RNA binding motif protein 10 RBM10 RNA/metal ion binding Xp11,23
.020 Down 208579_x_at Hs,473961 H2B histone family, member S H2BFS DNA binding 21q22,3
.027 Down 213134_x_at Hs,473420 BTG family, member 3 BTG3 Not available 21q21,1-q21,2
.028 Down 219300_s_at Hs,190621 Contactin-associated protein-like 2 CNTNAP2 Protein binding 7q35-q36
.029 Down 203628_at Hs,592020 Insulin-like growth factor 1 receptor IGF1R Nucleotide/protein binding, receptor
activity, ATP binding
15q26,3
.030 Down 201478_s_at Hs,4747 Dyskeratosis congenita 1, dyskerin DKC1 Telomerase activity/RNA binding Xq28
.032 Down 209911_x_at Hs,591797 Histone 1, H2bd HIST1H2BD DNA binding 6p21,3
.032 Down 218399_s_at Hs,34045 Cell division cycle–associated 4 CDCA4 Not available 14q32,33
.035 Down 203062_s_at Hs,632002 Mediator of DNA damage checkpoint 1 MDC1 Protein binding 6pter-p21,31
.036 Down 204099_at Hs,438823 SWI/SNF–related, matrix-associated,
actin-dependent regulator of
chromatin, subfamily D, member 3
SMARCD3 Transcription activity, receptor binding 7q35-q36
.036 Down 36936_at Hs,404119 Tissue-specific transplantation
antigen P35B
TSTA3 Catalytic activity, isomerase activity 8q24,3
.040 Down 201827_at Hs,250581 SWI/SNF–related, matrix-associated,
actin-dependent regulator of
chromatin, subfamily D, member 2
SMARCD2 Transcription coactivator activity,
protein binding
17q23-q24
.040 Down 204524_at Hs,459691 3-Phosphoinositide-dependent protein
kinase-1
PDPK1 Nucleotide/Protein binding, protein
kinase activity
16p13,3
.040 Down 222162_s_at Hs,534115 ADAM metallopeptidase with
thrombospondin type 1 motif, 1
ADAMTS1 Peptidase activity, integrin binding 21q21,2
.044 Down 209517_s_at Hs,521530 ash2 (absent, small, or homeotic)-like
(Drosophila)
ASH2L DNA/metal ion/promoter/protein binding,
histone methyltransferase activity,
transcription regular activity
8p11,2
.046 Down 212520_s_at Hs,327527 SWI/SNF–related, matrix-associated,
actin-dependent regulator of chromatin,
subfamily A, member 4
SMARCA4 DNA/Protein binding, transcription
factor activity
19p13,2
.047 Down 212977_at Hs,471751 Chemokine orphan receptor 1 CMKOR1 Signal transducer activity, receptor activity 2q37,3
.048 Down 211036_x_at Hs,7101 Anaphase-promoting complex subunit 5 ANAPC5 Ubiquitin-protein ligase activity, binding 12q24,31
.050 Down 210473_s_at Hs,99195 G protein–coupled receptor 125 GPR125 Actin/protein binding 4p15.31
.002 Up 202581_at Hs,274402 Heat shock 70-kDa protein 1B HSPA1B Nucleotide binding, ATP binding 6p21,3
.019 Up 200622_x_at Hs,515487 Calmodulin 3 (phosphorylase kinase, delta) CALM3 Calcium ion binding, protein binding 19q13,2-q13,3
.019 Up 209185_s_at Hs,442344 Insulin receptor substrate 2 IRS2 Signal transducer activity, receptor activity,
protein binding, cell proliferation
13q34
.021 Up 206788_s_at Hs,460988 Core-binding factor, beta subunit CBFB Transcription factor activity, protein binding 16q22,1
.026 Up 204039_at Hs,643434 CCAAT/enhancer binding protein
(C/EBP), alpha
CEBPA DNA binding, transcription factor activity,
RNA pol II transcription factor
19q13,1
.027 Up 219181_at Hs,465102 Lipase, endothelial LIPG Catalytic activity, protein binding 18q21,1
.028 Up 202046_s_at Hs,509447 Glucocorticoid receptor DNA binding
factor 1
GRLF1 Nucleotide binding, DNA binding, receptor
activity, GTP binding
19q13,3
.038 Up 209035_at Hs,82045 Midkine (neurite growth-promoting
factor 2)
MDK Cytokine activity, growth factor binding 11p11,2
.039 Up 200766_at Hs,121575 Cathepsin D (lysosomal aspartyl peptidase) CTSD Peptidase/hydrolase activity 11p15,5
.042 Up 202647_s_at Hs,486502 Neuroblastoma RAS viral (v-ras)
oncogene homolog
NRAS Nucleotide/GTP binding, GTPase activity 1p13,2
.043 Up 202519_at Hs,437153 MLX-interacting protein MLXIP DNA binding, transcription regulator activity 12q24,31
.045 Up 202540_s_a Hs,643495 3-Hydroxy-3-methylglutaryl-coenzyme
A reductase
HMGCR Oxidoreductase activity, NADP binding 5q13,3-q14
.045 Up 211985_s_at Hs,282410 Calmodulin 1 (phosphorylase kinase, delta) CALM1 Calcium ion binding, protein binding 14q24-q31
.046 Up 201552_at Hs,494419 Lysosomal-associated membrane protein 1 LAMP1 Not available 13q34
.046 Up 201285_at Hs,490347 Makorin, ring finger protein, 1 MKRN1 Chromatin binding, ligase activity, metal ion
binding, nucleic acid/protein binding
7q34
.048 Up 201329_s_at Hs,517296 v-ets Erythroblastosis virus E26 oncogene
homolog 2 (avian)
ETS2 DNA binding, transcription factor activity 21q22,3
.048 Up 202008_s_at Hs,356624 Nidogen 1 NID1 Calcium ion binding, protein binding,
extracellular matrix structural constituent
1q43
.048 Up 203183_s_at Hs,79335 SWI/SNF–related, matrix-associated,
actin-dependent regulator of chromatin,
subfamily D, member 1
SMARCD1 Transcription coactivator activity 12q13-q14
.049 Up 210916_s_at Hs,502328 CD44 molecule (Indian blood group) CD44 Receptor activity, protein binding 11p13
The GSTIMUL group consists of OV-90 samples with 5% FBS or with 5% of five ascites that stimulated cell migration (A1337, A1592, A1835, A1946, and A2085). The GnSTIMUL group consists of
OV-90 samples with no FBS or with 5% of the three ascites that did not stimulate cell migration (A1317, A1322, and A2090).
*All upward or downward changes observed in the gene expression levels were determined by microarray data using the Affymetrix HG-U133A GeneChip array and subsequently confirmed by Q-PCR. Up
refers to the gene expression level being higher in the GnSTIMUL group than in the GSTIMUL. Down refers to the gene expression level being lower in the GnSTIMUL group than in the GSTIMUL.
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with three nonstimulatory ascites (GnSTIMUL). Microarray analysis
identified 129 genes differentially expressed between the group of as-
cites that stimulated cell migration and the group that did not stimulate
cell migration. Among those genes, 40 were tested in Q-PCR. Pearson
correlations were calculated for themigratory effect (stimulatory or non-
stimulatory) of each ascites with a gene expression score, as shown in
Table 3. Among theses 40 genes, differential expression of 13 candidates
was confirmed by Q-PCR in a larger set of 31 ascites samples (Table 3).
Three candidates correlated significantly, but the expression pattern was
opposite to that expected by microarray analysis. Of 27 additional can-
didates tested by Q-PCR, no significant correlation between gene
expression and OV-90 cell migration could be established. The fact that
the differential expression of these genes was identified by microarray
analysis on a limited number of ascites samples (only eight), although
the validation was tested on 31 different ascites, could explain this poor
validation rate. These results also suggest that an extensive validation in a
supervised analysis by Q-PCR of gene candidates is essential to uncover
the richness of genes implicated in migration process.
Many genes differentially expressed in cells stimulated by the two
groups of ascites are closely related to the mitogen-activated protein
kinase (MAPK) pathway and apoptosis. A similar association between
MAPK-related genes and invasion was also observed in our recent
study [11], although different gene candidates were identified. In the
present study, the MAPK pathway–related genes include NRAS, ETS2,
Cathepsin D (CSTD), andHMGCR. Interestingly, recent studies suggest
that Cathepsin D could be responsible for the positive regulation of pro-
liferation, survival, motility, and invasion of fibroblasts by triggering ac-
tivation of ras/MAPK/Rds [23]. The Ras proteins were some of the first
proteins identified involving the regulation of cell growth [24]. Nearly
30% of human cancers are associated with mutations in the Ras genes
[25]. In ovarian cancer research, Ahmed et al. [26] showed that ascites
enhanced the activation of Ras by increasing Ras-GTP levels in the study
of four ovarian cancer cell lines. This study also presented evidence that
activation of Ras and downstream Erk pathway is involved in maintain-
ing growth, adhesion, and invasiveness of cancer cells. It was also recently
shown that a high expression of HMG-CoA reductase (HMGCR) in-
duced acceleration of the cholesterol synthesis pathway in cancer cells,
and this may have promoted Ras isoprenylation, a posttranslational
modification activating Ras [27]. In addition, the Ras–MAP kinase
signaling pathway leads to the phosphorylation of ETS transcription
Table 3. Correlation between Migration and Gene Expression.
Genes Median of Ratio in the GSTIMUL* Median of Ratio in the GnSTIMUL* Pearson Correlation P
HIST1H2Ac 1.14 1.37 −0.160 .389
FIP1L1 0.36 0.54 −0.160 .389
RBM10 0.41 0.47 −0.160 .389
H2BFS 0.81 0.81 −0.022 .905
BTG3 0.80 0.71 −0.160 .389
CNTNAP2 0.85 1.01 −0.298 .103
IGF1R 0.52 0.67 −0.298 .103
DKC1 0.60 0.61 −0.298 .103
hist1h2bd 0.79 1.12 −0.298 .103
CDCA4 1.08 1.38 0.116 .535
MDC1 1.02 1.38 −0.437† .014
SMARCD3 0.68 0.86 −0.254 .168
TSTA3 0.66 0.55 0.116 .535
SMARCD2 0.98 1.14 −0.160 .389
PDPK1 0.41 0.61 −0.160 .389
ADAMTS1 0.36 0.48 −0.160 .389
ASH2L 0.89 1.01 −0.298 .103
SMARCA4 0.68 0.76 −0.437† .014
CMKOR1 0.41 0.52 −0.160 .389
ANAPC5 0.58 0.76 −0.160 .389
GPR125 1.00 0.80 −0.437† .014
HSPA1B 1.00 1.49 −0.160 .389
CALM3 1.14 1.53 −0.254 .168
IRS2 1.60 2.49 −0.437† .014
CBFB 0.74 0.83 −0.160 .389
CEBPA 0.58 0.58 0.254 .168
LIPG 0.37 0.66 0.116 .535
GRLF1 0.80 0.84 −0.160 .389
MDK 0.52 0.82 −0.298 .103
CTSD 1 1.64 −0.437† .014
NRAS 0.74 1.04 −0.437† .014
MLXIP 0.53 0.84 −0.437† .014
HMGCR 0.59 1.25 −0.392† .029
CALM1 1.14 1.53 −0.298 .103
LAMP1 1.00 1.57 −0.392† .029
MKRN1 1.00 1.16 −0.116 .535
ETS2 0.47 0.83 −0.575‡ .001
NID1 0.56 0.72 −0.437† .014
SMARCD1 0.99 1.22 −0.575‡ .001
CD44 0.39 0.58 −0.392† .029
Pearson correlations were calculated between scored migration results (1 < 100% of migration and 2 ≥ 100% of migration) and scored genes expression (1 < median and 2 ≥ median) for the 40 candidates
quantified by Q-PCR.
*Gene expression ratio relative to OV-90 stimulated with FBS.
†Correlation is significant, P = .05.
‡Correlation is significant, P = .01.
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factors, including Ets-2, which plays an important role in the regula-
tion of growth and cell cycle–related genes [28] and protects cells from
apoptosis [29].
The other candidate genes identified in this study have been
linked to tumor growth and apoptosis. For example, CD44, a gene
upregulated in the group of nonstimulatory ascites, mediates the in-
teraction between ovarian carcinoma cells and the mesothelial cells
lining abdominal organs [30]. Through strong affinity binding to
the extracellular matrix in ovarian carcinoma cells, CD44 has been
shown to affect cell adhesion [30] and migration [31] as well as to
increase tumor growth [32]. In addition, increased CD44 expression
is associated with an increased expression of Bcl-2, an antiapoptotic
factor [33]. Mammary tumor cells that are deficient in Irs-2, another
candidate, have been shown to be significantly more sensitive to
apoptotic stimuli such as serum deprivation [29]. Conversely, BRG1/
SMARCA4, a member of the SWI/SNF complex, which is down-
regulated in OV-90 cells treated with stimulatory ascites, is required
for the growth arrest induction and cell senescence induced by p21
[34,35]. These results show that gene candidates that decrease the
migratory potential of OV-90 cells are also involved in growth pro-
motion and apoptotic protection of tumor cells, whereas genes up-
regulated by migratory ascites are involved in cell growth arrest. Taken
together, this suggests that cell migration and growth may be sequen-
tial events during tumor progression where cells need to stop growth
to be able to start migrating. Further experiments will be needed to con-
firm this hypothesis. In line with this is the fact that most gene can-
didates alone are not associated with survival of patients, which also
means that the migratory potential of tumor cell is necessary but in-
sufficient per se to affect the aggressive behavior of tumor cells.
In summary, this study provides evidence for some novel gene can-
didates and molecular pathways that may play an important role in
ovarian cancer cell migration. Combined with our previous research
[11], this work continues to define the importance of studying the
effect of both ascites and the tumor environment on ovarian cancer
cells. Our data also suggest that ascites may contain either positive or
negative regulators of tumor behaviors and can play a role in future
clinical outcomes. Future studies assessing the relative expression of
these candidates in clinical specimens will no doubt help to better
refine those that are important in ovarian cancer progression.
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